Shares of Akorn, Inc. (NASDAQ:AKRX) have received a consensus rating of “Hold” from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $29.17.

A number of research firms recently issued reports on AKRX. Piper Jaffray Companies set a $34.00 price objective on Akorn and gave the company a “hold” rating in a research report on Sunday, October 22nd. Royal Bank of Canada restated a “hold” rating and set a $34.00 price objective on shares of Akorn in a research report on Tuesday, October 3rd. Jefferies Group set a $34.00 price objective on Akorn and gave the company a “hold” rating in a research report on Sunday, October 29th. BidaskClub lowered Akorn from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 14th. Finally, Zacks Investment Research upgraded Akorn from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th.

Akorn (AKRX) opened at $32.72 on Tuesday. Akorn has a 12-month low of $17.74 and a 12-month high of $34.00. The stock has a market capitalization of $4,090.00, a P/E ratio of 55.46, a P/E/G ratio of 1.67 and a beta of 1.33. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16.

In other Akorn news, Director Brian Tambi sold 15,100 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total transaction of $503,585.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 28.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in AKRX. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Akorn by 22.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock valued at $108,000 after buying an additional 599 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Akorn by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock valued at $140,000 after buying an additional 626 shares during the period. Global Financial Private Capital LLC lifted its holdings in shares of Akorn by 13.1% in the second quarter. Global Financial Private Capital LLC now owns 9,524 shares of the company’s stock valued at $319,000 after buying an additional 1,105 shares during the period. Utah Retirement Systems lifted its holdings in shares of Akorn by 7.9% in the second quarter. Utah Retirement Systems now owns 16,400 shares of the company’s stock valued at $550,000 after buying an additional 1,200 shares during the period. Finally, Mutual of America Capital Management LLC lifted its holdings in shares of Akorn by 2.0% in the second quarter. Mutual of America Capital Management LLC now owns 72,190 shares of the company’s stock valued at $2,421,000 after buying an additional 1,429 shares during the period. Institutional investors own 73.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Akorn, Inc. (AKRX) Receives Average Rating of “Hold” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/09/akorn-inc-akrx-receives-average-rating-of-hold-from-analysts.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.